Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Updates in Diagnosis and Management of Bladder Cancer Patients: From...
share announcement

Updates in Diagnosis and Management of Bladder Cancer Patients: From Prevention to Surgery and Beyond

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 5981

Special Issue Editors

Dr. Giovanni E. Cacciamani

E-Mail Website
Guest Editor
Institute of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA
Interests: surgery; complications reporting; bladder cancer; artificial intelligence; patients safety; urology; minimally invasive surgery; adverse events; evidence-based medicine; quality reporting improvement
Special Issues, Collections and Topics in MDPI journals
Dr. Saum Ghodoussipour

E-Mail Website
Guest Editor
Division of Urology and Urologic Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Interests: bladder cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bladder cancer is the ninth most common malignant ailment and the fourteenth most common cause of cancer death worldwide. 

We are seeking high impact review or research papers for our upcoming Special Issue focusing on Updates in Diagnosis and Management of Bladder Cancer Patients: from Prevention to Surgery and Beyond.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Prevention of Bladder Cancer and patient counseling
  • Diagnostic options related to molecular signature/platform, AI, and novel urine/blood biomarkers related to therapy or molecular subtypes.
  • Diagnostic tools (Blue Light, NBI, ecc).
  • Surgical approaches (Open, Robotic or Laparoscopic techniques)
  • Surgical training for radical cystectomy with urinary diversion
  • Urinary Diversions (techniques and outcomes)
  • Enhanced after-recovery pathways
  • Perioperative complications and management
  • Strategies to improve the Quality of life
  • Chemotherapy and immunotherapy
  • Therapeutic options relating to new technology or biomarker implementations
  • Patient rehabilitation after Radical cystectomy
  • Follow up strategies
  • Treatment of metastatic bladder cancer

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Current Oncology.

Dr. Giovanni E. Cacciamani
Dr. Saum Ghodoussipour
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NBI cystoscopy
  • blue light cystoscopy
  • bladder cancer
  • ERAS
  • urothelial cancer
  • radical cystectomy
  • robotic radical cystectomy
  • smoking screening
  • immunotherapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

9 pages, 1478 KiB  
Article
The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy
by Giovanni E. Cacciamani, Afsaneh Barzi, Michael B. Eppler, Primo N. Lara, Jr., Chong-Xian Pan, Sumeet K. Bhanvadia, Parkash Gill, Monish Aron, Inderbir Gill and Sarmad Sadeghi
Cancers 2022, 14(23), 5984; https://doi.org/10.3390/cancers14235984 - 03 Dec 2022
Cited by 1 | Viewed by 1220
Abstract
The role of surgical experience and its impact on the survival requires further investigation. A cohort of patients undergoing radical cystectomy or anterior pelvic exenteration for localized bladder cancer between 2006 and 2013 at 1143 facilities across the United States was identified using [...] Read more.
The role of surgical experience and its impact on the survival requires further investigation. A cohort of patients undergoing radical cystectomy or anterior pelvic exenteration for localized bladder cancer between 2006 and 2013 at 1143 facilities across the United States was identified using the National Cancer Database and analyzed. Using overall survival (OS) as the primary outcome, the relationship between facility annual caseload (FAC) and facility annual surgical caseload (FASC) for those undergoing curative surgery was examined. Four volume groups (VG) depending on caseload using both FAC and FASC were defined. These included VG1: below 50th percentile, VG2: 50th–74th percentile, VG3: 75th–89th percentile, and VG4: 90th and above. Between 2006 and 2013, 27,272 patients underwent surgery for localized bladder cancer. The median OS was 59.66 months (95% CI: 57.79–61.77). OS improved significantly as caseload increased. The unadjusted median OS difference between VG1 and VG4 was 15.35 months (64.3 vs. 48.95 months, HR 1.19 95% CI: 1.13–1.25, p < 0.001) for FAC. This figure was 19.84 months (66.89 vs. 47.05 months, HR 1.25 95% CI: 1.18–1.32, p < 0.0001) for FASC. This analysis revealed a significant and clinically important survival advantage for curative bladder cancer surgery at highly experienced centers. Full article
(This article belongs to the Special Issue Updates in Diagnosis and Management of Bladder Cancer Patients: From Prevention to Surgery and Beyond)
►▼ Show Figures

Figure 1

11 pages, 933 KiB  
Article
Impact of Patient, Surgical, and Perioperative Factors on Discharge Disposition after Radical Cystectomy
by Giovanni E. Cacciamani, Ryan S. Lee, Daniel I. Sanford, Wesley Yip, Jie Cai, Gus Miranda, Siamak Daneshmand, Monish Aron, Hooman Djaladat, Inderbir S. Gill and Mihir Desai
Cancers 2022, 14(21), 5288; https://doi.org/10.3390/cancers14215288 - 27 Oct 2022
Cited by 1 | Viewed by 1206
Abstract
Radical cystectomy (RC) is a complex procedure associated with lengthy hospital stays and high complication and readmission rates. We evaluated the impact of patient, surgical, and perioperative factors on discharge disposition following RC at a tertiary referral center. From 2012 to 2019, all [...] Read more.
Radical cystectomy (RC) is a complex procedure associated with lengthy hospital stays and high complication and readmission rates. We evaluated the impact of patient, surgical, and perioperative factors on discharge disposition following RC at a tertiary referral center. From 2012 to 2019, all bladder cancer patients undergoing RC at our institution were identified (n = 1153). Patients were classified based on discharge disposition: to home or to continued facility-based rehabilitation centers (CFRs, n = 180 (15.61%) patients). On multivariate analysis of patient factors only, age [Risk Ratio (RR): 1.07, p < 0.001)], single marital status (RR: 1.09, p < 0.001), and living alone prior to surgery (RR: 2.55, p = 0.004) were significant predictors of discharge to CFRs. Multivariate analysis of patient, surgical, and perioperative factors indicated age (RR: 1.09, p < 0.001), single marital status (RR: 3.9, p < 0.001), living alone prior to surgery (RR: 2.42, p = 0.01), and major post-operative (Clavien > 3) complications (RR: 3.44, p < 0.001) were significant independent predictors of discharge to CFRs. Of note, ERAS did not significantly impact discharge disposition. Specific patient and perioperative factors significantly impact discharge disposition. Patients who are older, living alone prior to surgery, and/or have a major post-operative complication are more likely to be discharged to CFRs after RC. Full article
(This article belongs to the Special Issue Updates in Diagnosis and Management of Bladder Cancer Patients: From Prevention to Surgery and Beyond)
►▼ Show Figures

Figure 1

17 pages, 2433 KiB  
Article
Population-Based Assessment of Determining Predictors for Discharge Disposition in Patients with Bladder Cancer Undergoing Radical Cystectomy
by Raj A. Kumar, Kian Asanad, Gus Miranda, Jie Cai, Hooman Djaladat, Saum Ghodoussipour, Mihir M. Desai, Inderbir S. Gill and Giovanni E. Cacciamani
Cancers 2022, 14(19), 4613; https://doi.org/10.3390/cancers14194613 - 23 Sep 2022
Cited by 1 | Viewed by 1197
Abstract
Objective: To assess predictors of discharge disposition—either home or to a CRF—after undergoing RC for bladder cancer in the United States. Methods: In this retrospective, cohort study, patients were divided into two cohorts: those discharged home and those discharged to CRF. We examined [...] Read more.
Objective: To assess predictors of discharge disposition—either home or to a CRF—after undergoing RC for bladder cancer in the United States. Methods: In this retrospective, cohort study, patients were divided into two cohorts: those discharged home and those discharged to CRF. We examined patient, surgical, and hospital characteristics. Multivariable logistic regression models were used to control for selected variables. All statistical tests were two-sided. Patients were derived from the Premier Healthcare Database. International classification of disease (ICD)-9 (<2014), ICD-10 (≥2015), and Current Procedural Terminology (CPT) codes were used to identify patient diagnoses and encounters. The population consisted of 138,151 patients who underwent RC for bladder cancer between 1 January 2000 and 31 December 2019. Results: Of 138,151 patients, 24,922 (18.0%) were admitted to CRFs. Multivariate analysis revealed that older age, single/widowed marital status, female gender, increased Charlson Comorbidity Index, Medicaid, and Medicare insurance are associated with CRF discharge. Rural hospital location, self-pay status, increased annual surgeon case, and robotic surgical approach are associated with home discharge. Conclusions: Several specific patient, surgical, and facility characteristics were identified that may significantly impact discharge disposition after RC for bladder cancer. Full article
(This article belongs to the Special Issue Updates in Diagnosis and Management of Bladder Cancer Patients: From Prevention to Surgery and Beyond)
►▼ Show Figures

Figure 1

Other

Jump to: Research

11 pages, 553 KiB  
Systematic Review
Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review
by Shane Kronstedt, Sai Krishnaraya Doppalapudi, Joseph Boyle, Kevin Chua, Thomas L. Jang, Giovanni E. Cacciamani and Saum Ghodoussipour
Cancers 2022, 14(22), 5644; https://doi.org/10.3390/cancers14225644 - 17 Nov 2022
Cited by 1 | Viewed by 1661
Abstract
(1) Purpose: To assess the survival benefit for different times to adjuvant chemotherapy after a radical cystectomy. (2) Materials and Methods: We systematically searched PubMed®, Cochrane Central®, Scopus®, and Web of Science® library databases for original [...] Read more.
(1) Purpose: To assess the survival benefit for different times to adjuvant chemotherapy after a radical cystectomy. (2) Materials and Methods: We systematically searched PubMed®, Cochrane Central®, Scopus®, and Web of Science® library databases for original articles that looked at timing to adjuvant chemotherapy after radical cystectomy. Primary endpoints were five-year survival, progression free survival, and overall survival. Available multivariable hazard ratios and corresponding 95% CIs were included in the qualitative analysis. The risk of bias was completed for nonrandomized studies. (3) Results: Using PRISMA guidelines, our electronic search resulted in a total of 1862 records. After a detailed review, we selected four studies that addressed the impact of the timing of adjuvant chemotherapy for patients who underwent radical cystectomy. (4) Conclusion: A survival benefit was seen with an earlier administration of adjuvant chemotherapy, albeit a benefit persists for delayed chemotherapy post-radical cystectomy. A safe and ethical approach at this time would be to administer adjuvant chemotherapy as early in the postoperative period as possible, given the known survival benefit of such therapy (9–11% absolute survival benefit at five years). Full article
(This article belongs to the Special Issue Updates in Diagnosis and Management of Bladder Cancer Patients: From Prevention to Surgery and Beyond)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop